Detail akcie Spruce Bioscien Rg online

Business Summary: Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Spruce Biosciences Inc revenues decreased from $4.2M to $0K. Net loss decreased 17% to $24.3M. Revenues reflect Pharmaceutical segment decrease from $2M to $0K. Basic Earnings per Share excluding Extraordinary Items increased from -$53.70 to -$42.05.